CellCyte Genetics, Whatman, Nektar Therapeutics, Anesiva and
Hyaluron Contract Manufacturing have all had people on the move in
the world of pharmaceutical manufacturing.
In a turbulent year, Whatman has failed to meet its projected
revenue target by 1-3 per cent and changed its management but
resolved litigation that has been hanging over the firm since 2003.
A hiatus in leadership, changes in accounting rules and a
restructure in manufacturing have taken their toll on separations
specialist Whatman, whose sales growth for last year appears
stagnant, just 1 per cent up when adjusting for...
Separations specialist Whatman is starting to reap the benefits of
its acquisition of Schleicher & Schuell, but had a difficult
first half to the year with the group's combined revenues down
marginally compared to first-half...
UK-based separations specialist Whatman has fleshed out its plans
in the wake of the acquisition of Schleicher & Schuell, and
says it plans to cut 13 per cent of its workforce after 2004 sales
disappointed.
Setting aside the acrimony of a patent dispute, UK separations
company Whatman is to buy German rival Schleicher & Schuell for
€50.2 million, allowing it to narrow the gap between itself and the
main players Pall and Millipore.
UK-headquartered separations company Whatman is to sell its filter
cartridge business to Graver Technologies of the US for $2.1
million (€1.7m) in cash, continuing a string of divestments as it
copes with a decline in revenues.
UK-based separations specialist Whatman saw its turnover drop in
the first half of 2003, but operating profits leap on back of its
restructuring effort.
